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Abstract
Background: Caspases are important regulators and executioners in apoptosis pathway and have been defined as either
tumor suppressors or oncogenes. Polymorphisms in promoter and exon of caspase 9 were shown to confer genetic
susceptibility to multiple cancers, but the results were inconsistent. To accomplish a more precise estimation of the
relationship, a meta-analysis was performed.
Methodology/Principal Findings: We assessed published studies of the association between caspase 9 polymorphisms and
cancer risk from nine studies with 5,528 subjects for rs4645978, six studies with 2,403 subjects for rs105276 and two studies
for rs4645981. Overall meta-analysis indicated that no evidence of an association between rs4645978 and cancers was
found. Through the stratified analysis, statistically significant reduced cancer risks were observed among Caucasians (AG vs
AA: OR=0.81, 95% CI=0.66–0.99, Pheterogeneity=0.150 and the dominant model: OR=0.86, 95% CI=0.75–0.99,
Pheterogeneity=0.290) and prostate cancer. As for rs105276, Ex5+32G.A polymorphism was found with protective effect
in overall meta-analysis (AA vs GG: OR=0.75, 95% CI=0.60–0.92, Pheterogeneity=0.887; A vs G: OR=0.85, 95% CI=0.77–0.95,
Pheterogeneity=0.739 and the recessive model: OR=0.68, 95% CI=0.56–0.82, Pheterogeneity=0.309) and Asians group. While for
rs4645981, a statistically significant increase in risk of lung cancer was shown in Asians (T vs C: OR=1.23, 95% CI=1.07–1.42,
Pheterogeneity=0.399 and the dominant model: OR=1.22, 95% CI=1.04–1.43, Pheterogeneity=0.660).
Conclusions/Significance: Our meta-analysis suggests that the caspase 9 rs4645978 most likely contributes to decreased
susceptibility to cancer in Caucasians and prostate cancer. The A allele of rs105276 might be a protective factor for cancer,
especially for Asians. However, it seems that rs4645981 confers increased susceptibility to lung cancer in Asians.
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Introduction
Evasion of apoptosis is considered to be one of the hallmarks of
various human cancers [1]. This cell death modality is executed by
caspases (CASPs) and several upstream regulatory factors, which
play a crucial role in the development and progression of cancer
[2]. CASPs, a family of cysteine-dependent aspartate-specific
proteases, can be activated by two distinct but converging
pathways: the extrinsic or receptor-mediated pathway and the
intrinsic or mitochondrial pathway. Extrinsic (CASP8 and
CASP10) and intrinsic (CASP9) initiator CASPs transmit death
signals and activate effector CASPs (CASP3, CASP6 and CASP7),
which execute a coordinated program of proteolysis, resulting in
the destruction of critical cell structure [3].
CASP9, a member of the intrinsic pathway, plays a central role
in the mitochondrial apoptotic pathway. The intrinsic or
mitochondrial pathway is initiated by the release of cytochrome
c from mitochondria in response to a variety of cellular stress.
Released cytochrome c interacts with apoptotic protease activating
factor 1 (Apaf-1), procaspase-9 and deoxyadenosine triphosphate
(dATP) to form a multiprotein complex called apoptosome. Once
bound to the apoptosome, CASP9 is active, which subsequently
triggers a cascade of effector CASPs [4]. Some works have shown
that CASP 9 is the direct target for regulatory phosphorylation by
multiple protein kinases activated in response to extracellular
growth/survival factors, osmotic stress or during mitosis [2], which
is linked to tumorigenesis and responses to thermotherapy [5].
Recently, several candidate single nucleotide polymorphisms
(SNPs) in CASP9 gene have been reported in public databases
(http://www.ncbi.nlm.nih.gov/SNP). It is identified some of these
SNPs in the promoter or exon sequence of CASP9 as potential
biomarkers [eg. 21263A.G (rs4645978), 2712C.T (rs4645981)
and Ex5+32G..A (rs1052576)], which can modulate susceptibility
to cancer, such as those that occur in the lung [6,7,8], esophagus
[9], stomach [10,11], colorectal [12,13], liver [14], pancreas [15],
prostate [16,17], bladder [18], thyroid [19] and hemopoietic
system [20,21]. However, the observed associations of these studies
were inconsistent and a single study may be too underpowered to
detect the effect of the gene polymorphism on cancer, especially
when the sample size is relatively small. Hence, we performed a
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37443meta-analysis of all eligible studies to derive more precise
estimation of the association of CASP9 SNPs with cancer risks.
Materials and Methods
Publication search
We carried out a search in Medline, Embase, Chinese National
Knowledge Infrastructure (CNKI) and Wangfang databases,
covering all papers published between 1991 and 2012, with a
combination of the following keywords: ‘‘caspase 9/caspase-9/
CASP9’’, ‘‘polymorphism/single nucleotide polymorphisms/
SNPs/gene susceptibility/genetic variation’’ and ‘‘cancer/tu-
mor/carcinoma/neoplasia/neoplasm’’ (last search was updated
on 10 Mar 2012). We checked potentially relevant publications by
examining their titles and abstracts and all studies matching the
eligible criteria were retrieved. Besides the database search, the
bibliographies of the selected papers and reviews were also
examined by hand.
Criteria for inclusion and exclusion
Studies included in the current meta-analysis had to meet all the
following criteria: (a) evaluation of the CASP9 polymorphisms and
cancer risks, (b) use a case-control design, (c) sufficient published
data for estimating an odds ratio (OR) with 95% confidence
interval (CI). Accordingly, the following exclusion criteria were
also used: (a) reviews and repeated literatures, (b) not offering the
source of cases and controls and other essential information, (c) not
designed as case/control or cohort studies.
Data extraction
Data were independently abstracted by two investigators (Xu
and Li) using a standard protocol and data-collection form
according to the criteria listed above. Differences among
evaluators were resolved through discussion and rereading with
the third investigator (Wu). The following information was
extracted from each included study using a standardized data
collection protocol (File S1): the surname of first author,
publication date, country, ethnicity, cancer, characteristics of
control, genotyping methods, total number of cases and controls,
and numbers of cases and controls with various CASP9 genotypes,
respectively. Different ethnicity descents were categorised as
Caucasian, Asian and Mix (the original studies didn’t clarify the
race of the subjects or mixed races).
Statistical methods
OR corresponding to 95% CI was used to assess the strength of
association between CASP9 polymorphism and cancer. The
significance of the pooled OR was determined by the Z-test, and
P,0.05 was considered as statistically significant. For CASP9
rs4645978, the meta-analysis examined the association between G
allele and cancer risk compared with that for A allele (G vs A);
homozygote GG was contrasted with AA and recessive (GG vs
AA+AG) and dominant (AA+GA vs GG) models for allele G were
also used, so did rs10525576 and rs4645981. Subgroup analyses
were stratified by the study characteristics of racial descent and
tumor site, respectively.
Heterogeneity analysis was checked by the chi-square-based Q-
test [22]. A P-value.0.10 for the Q-test shows a lack of
heterogeneity among the studies, then the pooled OR estimate
of each study was calculated by the fixed-effects model (the
Mantel-Haenszel method) [23]. Otherwise, the random-effects
model (the DerSimonian and Laird method) [24] was used.
Hardy-Weinberg equilibrium (HWE) in the control group was
estimated by Fisher’s exact test and a P-value,0.05 was
considered significant. Publication bias was assessed by visual
inspection of funnel plots in which the standard error of log (OR)
of each study was plotted against its log (OR). Funnel plot
asymmetry was assessed by the method of Egger’s linear regression
test. The significance of the intercept was determined by the t-test
(P,0.05 was considered representative of statistically significant
publication bias) [25]. Sensitivity analysis was performed by
sequential omission of individual studies under various contrasts to
reflect the influence of the individual data to the pooled ORs. All
of the statistical analyses above were performed with STATA 9.2
(StataCorp, College Station, TX), using two-sided P-values.
Results
Study characteristics
Twenty-eight studies probing the relationship between CASP9
polymorphisms and cancer susceptibility were identified. During
the extraction of data, 13 articles were excluded, because they did
not provide allele frequencies needed for OR calculation, the
contents were lack of control, their contents mainly associated with
cancer therapy, or they studied fewer CASP9 SPNs (eg. rs1052571,
2308941, 4645980), leaving 15 eligible articles [6–8,10–21]
including 17 data sets based on the search criteria (Fig. 1). Two
studies [6,8] sorted the data about two kinds of CASP9
polymorphism, that is rs4645978 and rs4645981. Therefore, each
group in both studies was considered separately for pooling
analysis. The characteristics of selected studies are summarized in
Table 1. A total of 9 studies [6,8,11,13,15–19] involving 2,390
cases and 3,138 controls were ultimately analyzed for CASP9
rs4645978, six studies [7,10,12,14,20,21] involving 1,002 cases
and 1,401 controls for rs1052576 and two studies [6,8] for
rs4645981. As for CASP9 rs4645978, there were six subjects of
Caucasians [11,13,15–18] and three subjects of Asians [6,8,19].
For rs1052576, there were four groups of Asians [7,10,12,14] and
two of Mix [20,21]. With regard to rs4645981, both studies are
about lung cancer in Asians. The controls of all studies mainly
came from healthy population and matched for sex and age. All
articles used blood samples for genotyping assay. Except for three
studies [16–18], the distribution of genotypes in the controls was in
agreement with HWE.
Meta-analysis results
Frequencies of alleles were calculated for controls from the
corresponding genotype distribution. The variant alleles had
different representations among controls of Asian descent (0.412
for A allele in rs4645978, 0.608 for G allele in rs1052576) and
Caucasian descent (0.645 for G allele in rs4645978, 0.498 for A
allele in rs1052576).
For CASP9 rs4645978, five kinds of genetic models did not
produce significant association among 9 studies with relatively large
heterogeneity (Pheterogeneity=0.002–0.096). Through stratified anal-
yses, the heterogeneity of the subgroup significantly reduced. In the
stratified analysis by racial descent, statistically significantly
decreased cancer risks were found among Caucasian for AG vs
AA (OR=0.81, 95% CI=0.66–0.99, Pheterogeneity=0.150, Fig. 2)
and the dominant model (OR=0.86, 95% CI=0.75–0.99,
Pheterogeneity=0.290). No significant risks were found among Asians.
Carriage of the AG of rs4645978 was found to be associated with
protection from prostate cancer (AG vs AA: OR=0.64, 95%
CI=0.47–0.88, Pheterogeneity=0.925). No significant associations
were observed in lung cancer and other subgroups.
The overall OR with its 95% CI showed statistically association
between the CASP9 rs105276 polymorphism and the reduced risks
of cancers (AA vs GG: OR=0.75, 95% CI=0.60–0.92,
Caspase 9 Polymorphisms and Cancer Risk
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Pheterogeneity=0.739 and the recessive model: OR=0.68, 95%
CI=0.56–0.82, Pheterogeneity=0.309). In the subgroup analysis by
ethnicity, statistically significantly decreased cancer risks were
found among Asians for allele contrast (OR=0.69, 95%
CI=0.49–0.98, Pheterogeneity=0.827, Fig. 3), AG vs GG (OR=
0.79, 95% CI=0.67–0.94, Pheterogeneity=0.726) and the recessive
model (OR=0.55, 95% CI=0.40–0.75, Pheterogeneity=0.506).
As far as rs4645981, T allele had an effect of increasing the risk
of lung cancer in Asians (T vs C: OR=1.23, 95% CI=1.07–1.42,
Pheterogeneity=0.399; the dominant model: OR=1.22, 95%
CI=1.04–1.43, Pheterogeneity=0.660). All data are shown in
Table 2.
Publication bias
Begg’s funnel plot and Egger’s test were performed to assess the
publication bias of the literatures. The shapes of the funnel plot for
the comparison of the G allele and the A allele of CASP9
rs4645978 seemed symmetrical in all comparing models. Egger’s
test was used to provide statistical evidence for funnel plot
symmetry. The results still did not suggest any evidence of
publication bias (P=0.739 for G over A allele, P=0.776 for GG
versus AA, P=0.569 for AG versus AA, P=0.489 for dominant
contrast, P=0.752 for reserve contrast, Figure S1). Similarly, no
publication bias was detected for association of rs1052576
polymorphisms with cancer (Figure S2).
Sensitivity analysis
With regard to rs1052576, the results pattern was not impacted
by single study in all subgroup studies. As for rs4645978, one study
(Theodoropoulos et al. [15]) was considered as the main cause of
heterogeneity. After exclusion of this study, the heterogeneity no
longer existed and the result changed in GG vs AA, but others still
reached a negative association (Table S1).
Discussion
Some pioneers of cell death research suggested that pro-
apoptotic genes might act as tumor suppressors, whereas
oncogenes might fulfill antiapoptotic functions [2,26]. The efficient
of apoptosis in an organism may be the consequence of
polymorphisms in any gene regulating or executing apoptosis.
Analysis of these polymorphisms may thus help to identify cancer
susceptibility, prognosis and tailor treatments accordingly. Grow-
ing evidences, including meta-analysis [27] about extrinsic initiator
CASP8, have suggested that some CASP polymorphisms may
deregulated the expression and activity of caspase and have
attempted to correlate CASP polymorphisms with cancer risks.
In current study, we first summarized the data about the
association of intrinsic initiator CASP9 functional polymorphisms
and cancer risks. Although many SNPs located in the regions of
CASP9 were identified, most of them were not shown to affect
caspase expression and function. However, two SNPs in promoter,
CASP9 21263A.G (rs4645978) and 2712C.T (rs4645981),
were observed to alter the transcriptional activity of promoter. An
analysis of potential transcription factor-binding sites has shown
that the G-C haplotype of 21263A.G and 2712C.T polymor-
phisms have significantly higher transcriptional activity than the
A-T haplotype [6,16,28]. Therefore, it is possible that ‘‘higher
production’’ for CASP9 in G or C carriers offer protection against
the development of some cancers. Our study found a significantly
protective effect of CASP9 G variant in rs4645978 in the subgroups
of Caucasians and prostate cancers. Besides, the C allele in
rs4645981 also might be a protective factor for lung cancer in
Asians.
CASP9 (Ex5+32G.A, rs1052576) polymorphism encodes for a
glutamine to arginine amino acid change at codon 221 of the
protein, located at the border of the helix region of CASP9 [29].
This Q221R variant might lead to conformational changes in the
molecule, modify the affinity of this protein to Apaf-1, and
eventually influencing carcinogenesis [12,30]. The current results
Figure 1. Flow diagram of study identification.
doi:10.1371/journal.pone.0037443.g001
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37443Figure 2. Forest plot of cancer risk associated with rs4645978 under allele contrast in different types of cancers. The squares and
horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the study specific weight (inverse of the variance).
The diamond represents the pooled OR and 95% CI.
doi:10.1371/journal.pone.0037443.g002
Figure 3. Forest plot of cancer risk associated with rs1052576 under allele contrast (A vs G) in different ethnicity. The squares and
horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the study specific weight (inverse of the variance).
The diamond represents the pooled OR and 95% CI.
doi:10.1371/journal.pone.0037443.g003
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e37443showed that significant protective association of G/A polymor-
phism was found in overall meta-analysis and Asian subgroup. It is
possible that AA genotype of CASP9 Ex5+32G.A increases
apoptosome activity which provides a protection from various
disorders as well as cancer. Due to limited statistical power because
of relative small sample size, further evaluation was warranted to
confirm these results.
One important property of the gene polymorphisms is that their
incidence can vary substantially among different racial popula-
tions. In this meta-analysis, significant differences in the preva-
lence of the CASP9 rs4645978 A allele and rs1052576 G allele
among controls of Asians and Caucasian appeared. In the
subgroup analysis by ethnicity, we found the significant association
only in one ethnic but not in the other, suggesting genetic diversity
between different ethnicities.
In interpreting the results, some cautions should be applied. First,
relatively large heterogeneity existed in rs4645978 meta-analysis.
Through stratified analyses by tumor site and racial descent
respectively, heterogeneity reduced significantly. Therefore, we
presumed that the relatively large heterogeneity mainly results from
differences of ethnicity and tumor types. Simultaneously, the
heterogeneity might also be caused by the differences in the
selection of controls, age distribution and lifestyle factors. Moreover,
lack of the original data of the reviewed studies limited our further
evaluationofpotentialinteractionsbecause theinteractionsbetween
gene-to-gene,gene-to-environment,andevendifferentpolymorphic
loci of the same gene may modulate cancer risk. Finally, a relatively
limited number of studies and samples was analyzed for our
assessment. This was in part because the selected original studies
were performed with rather limited sample sets. Also, because the
reports included in our meta-analysis were limited to those
published in either English or Chinese, it is possible that some
relevant published and unpublished studies, likely to have null
results, were not included, possibly biasing the result, although the
result for publication bias was not statistically significant.
In summary, this meta-analysis supports that the caspase 9
rs4645978 most likely contributes to decreased susceptibility to
cancer in Caucasians and prostate cancer. For rs105276, the A
allele might be a protective factor for cancer, especially for Asians.
However, it seems that rs4645981 confers increased susceptibility
to lung cancer in Asians.
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Table 2. Main results of pooled ORs and stratification analysis of the rs4645978, rs1052576 and rs4645981 in caspase 9 on cancer
risk.
Caspase 9 GG vs AA AG vs AA G vs A Dominant model Recessive model
rs4645978 N OR (95% CI) Ph OR (95% CI) Ph OR (95% CI) Ph OR (95% CI) Ph OR (95% CI) Ph
Total 9 0.80(0.69–1.02)0.006 0.90(0.78–1.04)0.023 0.91(0.79–1.03)0.002 0.92(0.84–1.01)0.096 0.86(0.62–1.17)0.002
Cancer types
Prostate 2 0.96(0.69–1.35)0.842 0.64(0.47–0.88)0.925 0.94(0.78–1.13)0.828 0.83(0.65–1.05)0.12 1.23(0.89–1.69)0.850
Lung 2 0.88(0.70–1.11)0.465 1.03(0.88–1.19)0.717 0.96(0.86–1.07)0.518 0.99(0.88–1.14)0.987 0.83(0.67–1.03)0.477
Others 5 0.70(0.42–1.15)0.002 0.91(0.74–1.12)0.197 0.87(0.67–1.14)0.000 0.87(0.75–1.01)0.055 0.74(0.40–1.39)0.002
Ethnicity
Caucasian 5 0.79(0.53–1.19)0.001 0.81(0.66–0.99)0.150 0.96(0.86–1.07)0.002 0.86(0.75–0.99)0.290 0.93(0.64–1.25)0.001
Asian 3 0.85(0.68–1.06)0.465 1.03(0.90–1.18)0.932 0.95(0.86–1.05)0.605 0.99(0.88–1.12)0.331 0.78(0.67–1.03)0.319
Caspase 9 AA vs GG AG vs GG A vs G Dominant model Recessive model
rs1052576 N OR (95% CI) Ph OR (95% CI) Ph OR (95% CI) Ph OR (95% CI) Ph OR (95% CI) Ph
Total 6 0.75(0.60–0.92)0.887 0.94(0.80–1.10)1.000 0.85(0.77–0.95)0.739 0.92(0.81–1.05)0.999 0.68(0.56–0.82)0.309
Ethnicity
Asian 4 0.69(0.49–0.98)0.827 0.94(0.71–1.23)0.997 0.79(0.67–0.94)0.726 0.91(0.73–1.13)0.987 0.55(0.40–0.75)0.506
Mix 2 0.78(0.60–1.03)0.469 0.94(0.78–1.14)0.935 0.89(0.78–1.02)0.546 0.93(0.79–1.09)0.825 0.77(0.60–0.99)0.349
Caspase 9 TT vs CC CT vs TT T vs C Dominant model Recessive model
rs4645981 N OR (95% CI) Ph OR (95% CI) Ph OR (95% CI) Ph OR (95% CI) Ph OR (95% CI) Ph
Asian/Lung 2 1.45(0.95–1.21)0.174 1.09(0.71–1.68)0.243 1.23(1.07–1.42)0.399 1.22(1.04–1.43)0.660 1.33(0.87–2.02)0.172
N indicates number of studies involved; Ph: P-value of Q-test for heterogeneity test.
doi:10.1371/journal.pone.0037443.t002
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